Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewCB 839 is a potent non-competitive glutaminase (GLS1) inhibitor (IC50 = 24 nM for recombinant human GAC). The compound exhibits selectivity for GLS1 over GLS2. CB 839 displays antiproliferative activity in a triple-negative breast cancer cell line (GI50 values are 19 and 55 nM against MDA-MB-231 and HCC1806, respectively); it reduces glutamine consumption and glutamate production rates in HCC1806 cells. CB 839 displays significant antitumor activity as a single agent in a patient-derived TNBC xenografts model. CB 839 inhibits the growth of basal-like HER2 cell line JIMT-1 xenografts in mice, both as a single agent and in combination with Paclitaxel (Cat. No. 1097). CB 839 works with Erlotinib (Cat. No. 7194) to reduce glucose and glutamine uptake, increase energetic stress and activate the AMP-activated protein kinase (AMPK) pathway in EGFR (del19) non-small cell lung cancer xenografts in vivo. CB 839 is orally bioavailable.
分子量 | 571.58 |
公式 | C26H24F3N7O3S |
储存 | Store at -20°C |
纯度 | ≥98% (HPLC) |
CAS Number | 1439399-58-2 |
PubChem ID | 71577426 |
InChI Key | PRAAPINBUWJLGA-UHFFFAOYSA-N |
Smiles | O=C(NC1=NN=C(CCCCC2=NN=C(NC(CC3=CC=CC(OC(F)(F)F)=C3)=O)C=C2)S1)CC4=NC=CC=C4 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
DMSO | 57.16 | 100 |
以下数据基于产品分子量 571.58。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.75 mL | 8.75 mL | 17.5 mL |
5 mM | 0.35 mL | 1.75 mL | 3.5 mL |
10 mM | 0.17 mL | 0.87 mL | 1.75 mL |
50 mM | 0.03 mL | 0.17 mL | 0.35 mL |
参考文献是支持产品生物活性的出版物。
Gross et al (2014) Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol.Cancer Ther. 13 890 PMID: 24523301
Jacque et al (2015) Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood 126 1346 PMID: 26186940
Matre et al (2016) Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. Oncotarget 7 79722 PMID: 27806325
Momcilovic et al (2017) Targeted inhibition of EGFR and glutaminase induces metabolic crisis in EGFR mutant lung cancer. Cell Rep. 18 601 PMID: 28099841
Biancur et al (2017) Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism. Nat.Commun. 8 15965 PMID: 28671190
Zhou et al (2019) Estrogen inhibits autophagy and promotes growth of endometrial cancer by promoting glutamine metabolism. Cell Commun.Signal. 17 99 PMID: 31429768
If you know of a relevant reference for CB 839, please let us know.
关键词: CB 839, CB 839 supplier, CB839, potent, inhibits, orally, bioavailable, antitumor, non-competitive, inhibitors, glutaminases, GLS1, paclitaxel, erlotinib, antiproliferative, Glutaminase, 7591, Tocris Bioscience
目前没有该产品的评论。 Be the first to review CB 839 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.